Conflicts of interest
EPS
ONCOLOGY
H.D. received honoraria from AstraZeneca and Chugai Pharmaceutical. H.H. received honoraria from Amgen K.K., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kyorin Pharmaceutical Co. Ltd., Merck Biopharma Co. Ltd., MSD K.K., Novartis Pharmaceutical K.K., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd.; received consulting fees from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Guardant Health, Merck Biopharma Co. Ltd., Pfizer Japan Inc., Shanghai Haihe Biopharma, and Takeda Pharmaceutical Co. Ltd.; and received research funding from A2 Healthcare Corp., AbbVie Inc., Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin Ltd., Bristol Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., CMIC Shift Zero K.K., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Eisai Co. Ltd., EP-CRSU Co. Ltd., EPS Corp., EPS International Co. Ltd., Gritstone Oncology Inc., ICON Japan K.K., inVentiv Health Japan, Kissei Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Linical Co. Ltd., Merck Serono Co. Ltd., Merck Biopharma Co. Ltd., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Parexel International Corp., Pfizer Japan Inc., Pfizer R&D Japan G.K., Quintiles Inc./IQVIA Services Japan K.K., SymBio Pharmaceutical Ltd., Syneos Health, Taiho Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd. K.H. received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Lilly, MSD, Nippon Kayaku, Pfizer, and Takeda; and received research funding from AbbVie, AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Lilly, and MSD. S.I. received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Lilly, Ono Pharmaceutical, Pfizer, Taiho Pharmaceutical, and Takeda; and received research funding from AstraZeneca and Chugai Pharmaceutical. K.K. received honoraria from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Lilly, MSD, and Ono Pharmaceutical; and received research funding from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Lilly, MSD, and Ono Pharmaceutical. T.N. received honoraria from Ono Pharmaceutical and research grants from Ostuka Pharmaceutical. M.N. received honoraria from Bristol Myers Squibb and Ono Pharmaceutical. Y.O. received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly, Kyowa Hakko Kirin, MSD, Nippon Kayaku, Ono Pharmaceutical, Pfizer, and Taiho Pharmaceutical; and received research funding from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Dainippon Sumitomo, Janssen, Kissei, Kyorin, Lilly, Novartis, Ono Pharmaceutical, Pfizer, Taiho Pharmaceutical, and Takeda. I.O. received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Lilly, MSD Oncology, Ono Pharmaceutical, and Taiho Pharmaceutical; and received research funding from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Lilly, MSD Oncology, Ono Pharmaceutical, and Taiho Pharmaceutical. Y.S. received honoraria from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, MSD, Nippon Kayaku, Ono Pharmaceutical, Pfizer, and Taiho Pharmaceutical. S.S. received honoraria from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, MSD K.K., and Ono Pharmaceutical. H.T. received honoraria from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo Pharma, Eli Lilly, MSD, Ono Pharmaceutical, Takeda, and Taiho Pharmaceutical; and received research funding from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo Pharma, Eli Lilly, MSD, Ono Pharmaceutical, Takeda, and Taiho Pharmaceutical. T.Y. received honoraria from AstraZeneca K.K., Bristol Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., and Takeda Pharmaceutical Co. Ltd.; and received research funding from Bristol Myers Squibb Co. Ltd., Boehringer Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Delta-Fly Pharma, Janssen Pharmaceutical K.K., MSD, and Takeda Pharmaceutical Co. Ltd. J.B., R.G.G., and L.L. are employees of Bristol Myers Squibb and received stock ownership from Bristol Myers Squibb. T.F. and H.M. declare no competing interests.